-
公开(公告)号：US20140066427A1
公开(公告)日：2014-03-06
申请号：US14066276
申请日：2013-10-29
发明人： Gurmit S. Gill , Damian W. Grobelny
IPC分类号： C07D413/04 , C07D413/14
CPC分类号： A61K31/343 , A61K31/16 , A61K31/18 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/4164 , A61K31/4245 , C07C33/26 , C07C215/10 , C07C215/14 , C07C215/16 , C07C229/16 , C07C275/24 , C07C275/28 , C07C281/06 , C07C2602/42 , C07C2603/74 , C07D205/04 , C07D209/04 , C07D209/08 , C07D215/18 , C07D233/32 , C07D241/12 , C07D257/04 , C07D295/104 , C07D307/79 , C07D307/81 , C07D311/22 , C07D333/04 , C07D333/20 , C07D413/04 , C07D413/10 , C07D413/14 , C07F9/094 , C07F9/65586 , Y02A50/402 , Y02A50/47
摘要： The invention relates to novel compounds that have SIP receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression such as autoimmune response.
摘要翻译： 本发明涉及具有SIP受体调节活性的新化合物。 此外，本发明涉及包含至少一种本发明化合物的药物，其用于治疗由不适当的SIP受体调节活性或表达引起或与之相关的疾病和/或症状，例如自身免疫应答。 本发明的另一方面涉及包含至少一种本发明化合物的药物在制备用于治疗由不适当的SIP受体调节活性或表达引起或与之相关的疾病和/或症状的药物的用途，例如 自身免疫反应。
-
公开(公告)号：US20180228778A1
公开(公告)日：2018-08-16
申请号：US15751709
申请日：2016-08-11
申请人： Akaal Pharma Pty Ltd
发明人： Gurmit S. Gill , Damian W. Grobelny
IPC分类号： A61K31/4245 , A61K31/4439 , A61K31/4406 , A61K31/573 , A61K31/197 , A61K31/485 , A61K9/00 , A61K9/70 , A61K9/06 , A61K45/06 , A61K47/32
CPC分类号： A61K31/4245 , A61K9/0014 , A61K9/0019 , A61K9/0024 , A61K9/0031 , A61K9/0043 , A61K9/0046 , A61K9/0048 , A61K9/0053 , A61K9/0095 , A61K9/06 , A61K9/08 , A61K9/10 , A61K9/107 , A61K9/12 , A61K9/2004 , A61K9/48 , A61K9/7038 , A61K31/165 , A61K31/167 , A61K31/192 , A61K31/196 , A61K31/197 , A61K31/355 , A61K31/4406 , A61K31/4439 , A61K31/455 , A61K31/485 , A61K31/573 , A61K45/06 , A61K47/10 , A61K47/14 , A61K47/26 , A61K47/32 , A61K47/38 , A61K47/44 , A61K2300/00
摘要： Compositions comprising S1P receptor modulators and at least one compound selected from one or more of the group consisting of steroids, opioids and non-steroidal anti-inflammatory drugs are provided. The compositions find use in the treatment of disease, particularly inflammation and immune mediated disorders.
-
公开(公告)号：US09707205B2
公开(公告)日：2017-07-18
申请号：US14920780
申请日：2015-10-22
发明人： Gurmit S. Gill , Damian W. Grobelny
IPC分类号： A61K31/00 , A61K31/343 , A61K31/16 , A61K31/18 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/4164 , C07C33/26 , C07C215/10 , C07C215/14 , C07C215/16 , C07C229/16 , C07C275/24 , C07C275/28 , C07C281/06 , C07D205/04 , C07D209/04 , C07D209/08 , C07D215/18 , C07D233/32 , C07D241/12 , C07D257/04 , C07D295/104 , C07D307/79 , C07D307/81 , C07D311/22 , C07D333/04 , C07D333/20 , C07D413/10 , C07D413/14 , C07F9/09 , C07F9/6558 , C07D413/04 , A61K31/4245
CPC分类号： A61K31/343 , A61K31/16 , A61K31/18 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/4164 , A61K31/4245 , C07C33/26 , C07C215/10 , C07C215/14 , C07C215/16 , C07C229/16 , C07C275/24 , C07C275/28 , C07C281/06 , C07C2602/42 , C07C2603/74 , C07D205/04 , C07D209/04 , C07D209/08 , C07D215/18 , C07D233/32 , C07D241/12 , C07D257/04 , C07D295/104 , C07D307/79 , C07D307/81 , C07D311/22 , C07D333/04 , C07D333/20 , C07D413/04 , C07D413/10 , C07D413/14 , C07F9/094 , C07F9/65586 , Y02A50/402 , Y02A50/47
摘要： The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.
-
公开(公告)号：US09193716B2
公开(公告)日：2015-11-24
申请号：US14066276
申请日：2013-10-29
发明人： Gurmit S. Gill , Damian W. Grobelny
IPC分类号： A61K31/00 , C07D413/04 , A61K31/16 , A61K31/18 , A61K31/343 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/4164 , C07C33/26 , C07C215/10 , C07C215/14 , C07C215/16 , C07C229/16 , C07C275/24 , C07C275/28 , C07C281/06 , C07D205/04 , C07D209/04 , C07D209/08 , C07D215/18 , C07D233/32 , C07D241/12 , C07D257/04 , C07D295/104 , C07D307/79 , C07D307/81 , C07D311/22 , C07D333/04 , C07D333/20 , C07D413/10 , C07D413/14 , C07F9/09 , C07F9/6558
CPC分类号： A61K31/343 , A61K31/16 , A61K31/18 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/4164 , A61K31/4245 , C07C33/26 , C07C215/10 , C07C215/14 , C07C215/16 , C07C229/16 , C07C275/24 , C07C275/28 , C07C281/06 , C07C2602/42 , C07C2603/74 , C07D205/04 , C07D209/04 , C07D209/08 , C07D215/18 , C07D233/32 , C07D241/12 , C07D257/04 , C07D295/104 , C07D307/79 , C07D307/81 , C07D311/22 , C07D333/04 , C07D333/20 , C07D413/04 , C07D413/10 , C07D413/14 , C07F9/094 , C07F9/65586 , Y02A50/402 , Y02A50/47
摘要： The invention relates to novel compounds that have SIP receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression such as autoimmune response.
摘要翻译： 本发明涉及具有SIP受体调节活性的新化合物。 此外，本发明涉及包含至少一种本发明化合物的药物，其用于治疗由不适当的SIP受体调节活性或表达引起或与之相关的疾病和/或症状，例如自身免疫应答。 本发明的另一方面涉及包含至少一种本发明化合物的药物在制备用于治疗由不适当的SIP受体调节活性或表达引起或与之相关的疾病和/或症状的药物的用途，例如 自身免疫反应。
-
-
-
搜索结果
4 条记录 (耗时 0.054 秒)
